A US$239 million deal led by Chinese drugmaker Shanghai Pharmaceuticals Holding Co., Ltd. and private equity firm Primavera Capital to acquire Australian vitamins maker Vitaco Holdings has won approval from Australia's Foreign Investment Review Board (FIRB), clearing a major roadblock and pushing the deal closer to completion.